Latus Bio Inc. has launched with a focus on developing novel gene therapy candidates for central nervous system (CNS) disorders. An initial close of $54 million in series A financing will support the company.
The TEAD family of transcription factors are regulated by the Hippo tumor suppressor pathway and they act by binding the co-activators YAP and TAZ that drive the transcription of genes involved in cell survival, proliferation, migration, differentiation and resistance.
There is still a need for developing more potent and broadly neutralizing vaccines against SARS-CoV-2 with improved durability. At the recent ESCMID meeting, Astrazeneca plc presented a new mRNA vaccine against the SARS-CoV-2 virus that encodes for self-assembling virus-like particle (VLP) antigens.
Novel HIV-1 vaccine strategies should elicit potent and broad immunity against the viral envelope (Env) glycoprotein. Particle presentation of Env has shown promise in animal studies, but has several problems that limit their clinical application.
Japanese researchers have transplanted human induced pluripotent stem cells (iPSCs) in a primate model of myocardial infarction and were able to restore heart muscle and function in monkeys. Developed by Tokyo-based Heartseed Inc., the grafted iPSCs consist of clusters of purified heart muscle cells (cardiomyocyte spheroids) that are injected into the myocardial layer of the heart. Published in Circulation on April 26, 2024, the study showed that the cardiomyocyte spheroids survived long term and showed improved contractile function with low occurrence of post-transplant arrhythmias.
Gilead Sciences Inc. has patented 4'-Thionucleoside analogues acting as viral replication inhibitors reported to be useful for the treatment of HIV infection.
RSS
